TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06495723: Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PT

Sponsor: Xenothera SAS · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,600,130

Rescue Site Savings

+$5,694,150

Unlock Full NCT06495723 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06495723 Rescue Dossier →